v3.20.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Costs and Expenses:    
Research and development $ 4,086,883 $ 2,314,701
General and administrative 2,259,631 1,788,414
Total costs and expenses 6,346,514 4,103,115
Loss from operations (6,346,514) (4,103,115)
Sale of New Jersey net operating loss 1,073,289
Other income, net 227,327 52,407
Net loss (5,045,898) (4,050,708)
Preferred stock series A accumulated dividends (146,786)
Preferred stock series B accumulated dividends (170,700) (118,250)
Net loss attributable to common shareholders $ (5,216,598) $ (4,315,744)
Net loss attributable to common shareholders per share - basic and diluted $ (0.03) $ (0.04)
Weighted average common shares outstanding:    
Basic and diluted 191,671,153 117,366,673
Other comprehensive income/(loss), net of tax    
Unrealized gain on securities available-for-sale $ 523,246
Other comprehensive income/(loss), net of tax 523,246
Comprehensive loss attributable to shareholders $ (4,522,652) $ (4,050,708)

Source